Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs Tretinoin (Primary)
- Indications Acne vulgaris
- Focus Registrational; Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 04 Sep 2020 Results (n=1640) of post-hoc pooled analysis assessing effects of tretinoin 0.05% lotion on patient-reported quality of life in two studies (NCT02932306 & NCT02965456), published in the American Journal of Clinical Dermatology.
- 01 Mar 2020 Results (n=1640) from two double-blind placebo-controlled 12-week studies (V01-121A301 and V01-121A302) assessing safety and tolerability in subgroups were published in the Journal of Dermatological Treatment
- 11 Oct 2018 According to a Bausch & Lomb media release, the results were published in Journal of Drugs in Dermatology.